Page last updated: 2024-11-05

fentanyl citrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

fentanyl citrate : The citric acid salt of fentanyl, comprising equimolar amounts of citric acid and fentanyl. A mu-opioid receptor agonist, it is a potent opioid analgesic used in the management of labour pain, postoperative pain, and chronic intractable cancer pain. It is also widely used as the analgesic component of balanced anaesthesia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13810
CHEMBL ID688
CHEBI ID31602
SCHEMBL ID40733
MeSH IDM0330379

Synonyms (83)

Synonym
unii-mun5lyg46h
abstral
fentanyl citrate [usan:usp:ban:jan]
onsolis
rapinyl
mun5lyg46h ,
oralet
mcn-jr-4263-49
propionanilide, n-(1-phenethyl-4-piperidyl)-, citrate (1:1)
n-(1-phenethyl-4-piperidyl)propionanilide citrate (1:1)
fentanyl citrate
propanamide, n-phenyl-n-(1-(2-phenylethyl)-4-piperidinyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
fentanyl dihydrogen citrate
r 5240
n-(1-phenethyl-4-piperidyl)propionanilide citrate
sublimaze preservative free
fentaz
einecs 213-588-0
n-(1-phenethyl-4-piperidyl)propionanilide dihydrogen citrate
fentanyl citrate preservative free
r-4263
n-(1-phenethyl-4-piperidinyl)propionanilide dihydrogen citrate
actiq
mcn-jr 4263
phentanyl citrate
leptanal
D01399
fentanyl citrate (jp17/usp)
fentora (tn)
oralet (tn)
990-73-8
abstral (tn)
lazanda (tn)
instanyl
kw-2246
CHEMBL688
fentanyl citrate cii
fentanyl buccal
CHEBI:31602 ,
n-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide 2-hydroxypropane-1,2,3-tricarboxylate
fentanyl monocitrate
n-(1-phenethylpiperidin-4-yl)-n-phenylpropionamide citrate
n-phenyl-n-[1-(2-phenylethyl)-4-piperidyl]propanamide citrate
lazanda
fentanyl citrate salt
fentanyl citrate [green book]
fentanyl citrate cii [usp-rs]
fentanyl citrate [usp monograph]
innovar component fentanyl citrate
fentanyl citrate [ema epar]
fentanyl citrate [jan]
fentanyl citrate [orange book]
fentanyl citrate component of innovar
fentanyl citrate [ep monograph]
fentanyl citrate [mart.]
fentanyl citrate [usan]
fentanyl citrate [mi]
fentanyl citrate [vandf]
fentanyl citrate [who-dd]
SCHEMBL40733
IVLVTNPOHDFFCJ-UHFFFAOYSA-N
n-phenyl-n-[1-(2-phenylethyl)-4-piperidinyl]propanamide citrate
AKOS024457504
DTXSID80243933 ,
fentanyl citrate, united states pharmacopeia (usp) reference standard
fentanyl citrate, european pharmacopoeia (ep) reference standard
2-hydroxypropane-1,2,3-tricarboxylic acid;n-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Q27104201
n-(1-phenethylpiperidin-4-yl)-n-phenylpropionamide 2-hydroxypropane-1,2,3-tricarboxylate
n-phenyl-n-(1-(2-phenylethyl)-4-piperidyl)propanamide citrate
fentanyl nasal spray
fentyl
fentanyl citrate (mart.)
fentanyl citrate (ep monograph)
n-phenyl-n-(1-(2-phenylethyl)piperidin-4-yl)propanamide 2-hydroxypropane-1,2,3-tricarboxylate
dtxcid10166424
n-(1-phenethylpiperidin-4-yl)-n-phenylpropanamide monocitrate
transmucosal fentanyl citrate
fentanyl citrate (usan:usp:ban:jan)
fentanyl citrate (usp monograph)
fentanyl citrate cii (usp-rs)
fentanyl.citrate, 1mg/ml in methanol
fentanyl.citrate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
citrate saltA salt of citric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID623185Agonist activity at delta opioid receptor in ICR mouse vas deferens assessed as inhibition of MVD contraction height2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.
AID1188863Antinociceptive activity in iv dosed NMRI mouse assessed as increase in latency for tail withdrawal from radiant heat source by tail flick test2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.
AID623181Agonist activity at mu opioid receptor in Hartley guinea pig ileum/longitudinal muscle with myenteric plexus assessed as inhibition of PL-017-induced GPI contraction height2011Bioorganic & medicinal chemistry, Oct-15, Volume: 19, Issue:20
Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.
AID23705Partition coefficient (logP)1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Conformationally restrained fentanyl analogues. 2. Synthesis and analgetic evaluation of perhydro-1,6-naphthyridin-2-ones.
AID1130775Partition coefficient, log P of the compound at 1 mg/ml at pH 7 by RP-HPLC analysis1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
4-Anilidopiperidine analgesics. 2. A study of the conformational aspects of the analgesic activity of the 4-anilidopiperidines utilizing isomeric N-substituted 3-(propananilido)nortropane analogues.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1130776Analgesic activity in sc dosed ICR albino mouse assessed as dose required for 50% induction of analgesia in thermal stimulus challenge after 20 mins by tail flick test1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
4-Anilidopiperidine analgesics. 2. A study of the conformational aspects of the analgesic activity of the 4-anilidopiperidines utilizing isomeric N-substituted 3-(propananilido)nortropane analogues.
AID1188864Antinociceptive activity in orally dosed NMRI mouse assessed as increase in latency for tail withdrawal from radiant heat source by tail flick test2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.
AID114828Compound was evaluated in vivo for the analgesic activity by administrating sc. in ICR Swiss male mice by using a modification of the D'Amour-Smith tail-flick assay1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Conformationally restrained fentanyl analogues. 2. Synthesis and analgetic evaluation of perhydro-1,6-naphthyridin-2-ones.
AID1188866Antinociceptive activity in orally dosed NMRI mouse assessed as time duration showing >20% maximum possible antinociceptive efficacy by tail flick test2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.
AID1188865Antinociceptive activity in iv dosed NMRI mouse assessed as time duration showing >20% maximum possible antinociceptive efficacy by tail flick test2014ACS medicinal chemistry letters, Aug-14, Volume: 5, Issue:8
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]